Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Axsome Therapeutics, Inc. (AXSM) Q1 2020 Earnings Call Transcript
06:00pm, Saturday, 09'th May 2020
During today's call, we will be making certain forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are only made as of today's date, a
Why Jazz Pharmaceuticals' Symphony of Growth Is About to End
12:10pm, Saturday, 09'th May 2020
Competition is about to ramp up significantly in the $1.7 billion market for treating chronic sleep disorder.
Is Axsome Therapeutics a Screaming Buy?
10:47am, Saturday, 09'th May 2020
The past few weeks have been quite busy for Axsome Therapeutics (NASDAQ: AXSM), notching two wins and one failure in late-stage clinical trials. On March 30, the company reported its drug AXS-05 fail
Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
11:00am, Friday, 08'th May 2020
Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further.
The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda
12:00am, Friday, 08'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 7)
• Acceleron Pharma Inc (...
Here's Why Axsome Therapeutics Rocketed 61.5% Higher in April
07:39pm, Sunday, 03'rd May 2020
Shares of Axsome Therapeutics (NASDAQ: AXSM), a clinical-stage biopharmaceutical company, rocketed 61.5% in April, according to data from S&P; Global Market Intelligence. March was a rough month for
Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More
12:55pm, Friday, 01'st May 2020
Remdesivir, the investigational Gilead Sciences antiviral drug, looks more likely than ever to become the first treatment authorized by the FDA to treat
SunTrust Banks Equities Analysts Lift Earnings Estimates for Axsome Therapeutics Inc (NASDAQ:AXSM)
09:36am, Friday, 01'st May 2020
Axsome Therapeutics Inc (NASDAQ:AXSM) – SunTrust Banks lifted their FY2021 earnings estimates for Axsome Therapeutics in a report issued on Monday, April 27th. SunTrust Banks analyst J. Lee now fore
There May Be a New First-Line Treatment for Depression
12:00pm, Thursday, 30'th Apr 2020
Key details in an antidepressant's clinical trial may signal a revolutionary therapy for patients.
Axsome Therapeutics to Report First Quarter 2020 Financial Results on May 8, 2020
11:00am, Thursday, 30'th Apr 2020
Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will repor
SunTrust Banks Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $200.00
07:58am, Thursday, 30'th Apr 2020
Axsome Therapeutics (NASDAQ:AXSM) had its target price increased by SunTrust Banks from $145.00 to $200.00 in a research report sent to investors on Monday morning, The Fly reports. They currently hav
Axsome Therapeutics (NASDAQ:AXSM) Trading 4% Higher on Analyst Upgrade
05:22am, Wednesday, 29'th Apr 2020
Axsome Therapeutics Inc (NASDAQ:AXSM)’s stock price was up 4% during trading on Tuesday after Guggenheim raised their price target on the stock from $158.00 to $200.00. Guggenheim currently has a bu
Axsome Shares Jump 25% on Alzheimer's Study Results
03:16pm, Tuesday, 28'th Apr 2020
Clinical trial of AX-05 showed drug reduces patient agitation Continue reading...
Axsome Shares Jump 25% on Alzheimer€™s Study Results
02:38pm, Tuesday, 28'th Apr 2020
Axsome Shares Jump 25% on Alzheimer’s Study Results, Stocks: AXSM,LLY,RHHBY,ACIU,MOR,ESALY,BIIB, release date:Apr 27, 2020
U.S. RESEARCH ROUNDUP- American Tower, Ferrari, Walt Disney
01:41pm, Tuesday, 28'th Apr 2020
Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including American Tower, Ferrari and Walt Disney, on Tuesday.
HIGHLIGHTS
* Amer
